Date: 18.11.2010
Authors: Eduardo Ansorena, Elisa Garbayo, José L Lanciego, María S Aymerich, María J Blanco-Prieto
The administration of glial cell line-derived neurotrophic factor (GDNF) has emerged as a promising strategy for the treatment of several diseases of the nervous system as Parkinson's disease, amyotrophic lateral sclerosis, spinal cord injury and nerve regeneration as well as ocular diseases and drug addictions. A procedure for the purification of human recombinant glycosylated GDNF using a mammalian expression system as the source of the protein is discussed in the present paper. The neurotrophic factor was purified using cation exchange chromatography and gel filtration. A human cell line was chosen as the source of therapeutic protein, since a recombinant protein with a structure and glycosylation pattern equivalent to the native form is desirable for its prospective therapeutic utilization. The activity of the highly pure protein obtained was confirmed with a cell based bioassay. The purified protein is suitable for its in vivo evaluation in animals and for possible subsequent clinical application.
International journal of pharmaceutics. 01/10/2009;
ISSN: 1873-3476
DOI: 10.1016/j.ijpharm.2009.10.015
For more information make free registration on the scientific network Research Gate and see full text.
Gate2Biotech - Biotechnology Portal - All Czech Biotechnology information in one place.
ISSN 1802-2685
This website is maintained by: CREOS CZ
© 2006 - 2024 South Bohemian Agency for Support to Innovative Enterprising (JAIP)
Interesting biotechnology content:
Biotech events - Interesting events in biotech segment
Cancer cells - Czech Scientists are Working to Find the Achilles‘ Heel of Cancer Cells
Mosquito-spreading drones could slash the spread of disease
New molecule triggers burst of white blood cells to fight infections